RGRX (Regenerx Biopharmaceuticals) LT-Debt-to-Total-Asset: 1.50 (As of Mar. 2023)


What is Regenerx Biopharmaceuticals LT-Debt-to-Total-Asset?

Regenerx Biopharmaceuticals RGRX LT-Debt-to-Total-Asset is 1.50 as of Mar. 2023.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Regenerx Biopharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Mar. 2023 was 1.50.

Regenerx Biopharmaceuticals's long-term debt to total assets ratio increased from Mar. 2022 (1.24) to Mar. 2023 (1.50). It may suggest that Regenerx Biopharmaceuticals is progressively becoming more dependent on debt to grow their business.

Regenerx Biopharmaceuticals  (OTCPK:RGRX) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Regenerx Biopharmaceuticals LT-Debt-to-Total-Asset Related Terms

Regenerx Biopharmaceuticals LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Regenerx Biopharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regenerx Biopharmaceuticals LT-Debt-to-Total-Asset Chart

Regenerx Biopharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.99 1.73 0.89 3.67

Regenerx Biopharmaceuticals Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.24 1.70 2.33 3.67 1.50

Regenerx Biopharmaceuticals LT-Debt-to-Total-Asset Calculation

Regenerx Biopharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

LT Debt to Total Assets (A: Dec. 2022 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2022 )/Total Assets (A: Dec. 2022 )
=1.403/0.382
=3.67

Regenerx Biopharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2023 is calculated as

LT Debt to Total Assets (Q: Mar. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2023 )/Total Assets (Q: Mar. 2023 )
=0.28/0.187
=1.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 1.50 mean?
Regenerx Biopharmaceuticals (RGRX) has a LT-Debt-to-Total-Asset of 1.50 as of Mar. 2023. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Regenerx Biopharmaceuticals and its competitors.
Is Regenerx Biopharmaceuticals' LT-Debt-to-Total-Asset too high?
Regenerx Biopharmaceuticals' current LT-Debt-to-Total-Asset is 1.50.
How does Regenerx Biopharmaceuticals' LT-Debt-to-Total-Asset compare to MYMX and RGMP?
Regenerx Biopharmaceuticals' LT-Debt-to-Total-Asset of 1.50 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Regenerx Biopharmaceuticals and its competitors. Regenerx Biopharmaceuticals's current LT-Debt-to-Total-Asset is 1.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenerx Biopharmaceuticals stock overvalued right now?
Regenerx Biopharmaceuticals (RGRX) has a current LT-Debt-to-Total-Asset of 1.50. The current LT-Debt-to-Total-Asset is 1.50. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Regenerx Biopharmaceuticals (RGRX), the current LT-Debt-to-Total-Asset is 1.50 as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regenerx Biopharmaceuticals Business Description

Address 15245 Shady Grove Road, Suite 470, Rockville, MD, USA, 20850
Regenerx Biopharmaceuticals Inc is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Its operations are confined to one business segment: the development and marketing of product candidates based on Thymosin Beta 4 (Tß4), an amino acid peptide. The company has formulated Tß4 into three distinct product candidates in clinical development: RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-137, a topical gel for dermal wounds and reduction of scar tissue; and RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration.